Key result
Disease-modifying therapies for ATTR-CM require an intermediate decision-making framework to balance patient-first clinical care with sustainable healthcare resource utilization.
Answers are grounded in this paper and cite their sources.
Proposes a new 'Layer 1.5' decision-making framework to balance ethical, patient-centered care with healthcare sustainability in the era of high-cost, long-term disease-modifying therapies for ATTR-CM.
Background: Disease-modifying therapies (DMTs) for transthyretin amyloid cardiomyopathy (ATTR-CM), including transthyretin stabilizers and small interfering RNA-based therapeutics, represent a major advance in cardiovascular medicine and have substantially improved clinical outcomes. However, this therapeutic success has generated a dilemma. As diagnostic strategies expand and survival improves, particularly among older adults, the population receiving long-term, high-cost therapy continues to grow. This amplifies both cumulative societal and healthcare system burdens. Unstructured or indiscriminate use of DMTs risks exhausting shared healthcare resources and paradoxically undermining “patient-first” care for future patients.
No takes yet. Share an insight, caveat, or question.
Yuichi Baba (2026) conducted an editorial in Transthyretin amyloid cardiomyopathy (ATTR-CM). Disease-modifying therapies was evaluated. Disease-modifying therapies for ATTR-CM require an intermediate decision-making framework to balance patient-first clinical care with sustainable healthcare resource utilization.
Synapse has enriched 10 related papers. Consider them for comparative context: